Ambient

Neuron-Specific
Enolase (NSE) is recognized as a biomarker for small cell lung cancer. It is
secreted from neuroendocrine cells as well as neurogenic tumors. Its levels in
NSE-secreting neoplasms correlate with tumor mass and tumor metabolic activity.

Neuron-Specific
Enolase (NSE) is recognized as a biomarker for small cell lung cancer. It is
secreted from neuroendocrine cells as well as neurogenic tumors. Its levels in
NSE-secreting neoplasms correlate with tumor mass and tumor metabolic activity.

Neuron-Specific
Enolase (NSE) is recognized as a biomarker for small cell lung cancer. It is
secreted from neuroendocrine cells as well as neurogenic tumors. Its levels in
NSE-secreting neoplasms correlate with tumor mass and tumor metabolic activity.

Neuron-Specific Enolase (NSE) is recognized as a biomarker for small cell lung cancer. It is secreted from neuroendocrine cells as well as neurogenic tumors. Its levels in NSE-secreting neoplasms correlate with tumor mass and tumor metabolic activity.

Neuron-Specific Enolase (NSE) is recognized as a biomarker for small cell lung cancer. It is secreted from neuroendocrine cells as well as neurogenic tumors. Its levels in NSE-secreting neoplasms correlate with tumor mass and tumor metabolic activity.

Neuron-Specific Enolase (NSE) is recognized as a biomarker for small cell lung cancer. It is secreted from neuroendocrine cells as well as neurogenic tumors. Its levels in NSE-secreting neoplasms correlate with tumor mass and tumor metabolic activity.

BNP and NT-proBNP are separated from precursor molecule proBNP via proteolytic processing. The BNP and NT-proBNP level in blood are proportional to the severity of cardiac dysfunction. They can be used for diagnosis of congestive heart failure (CHF).

BNP and NT-proBNP are separated from precursor molecule proBNP via proteolytic processing. The BNP and NT-proBNP level in blood are proportional to the severity of cardiac dysfunction. They can be used for diagnosis of congestive heart failure (CHF).

BNP and NT-proBNP are separated from precursor molecule proBNP via proteolytic processing. The BNP and NT-proBNP level in blood are proportional to the severity of cardiac dysfunction. They can be used for diagnosis of congestive heart failure (CHF).